N/A
N/A
N/A
N/A
N/A
Not Enrolling
Both
Immunosuppression, Hepatocellular Carcinoma, Liver Transplantation, Post-operative Complications
Both
Immunosuppression, Hepatocellular Carcinoma, Liver Transplantation, Post-operative Complications
Trial Information
Inclusion Criteria:
- All liver transplantation patients with hepatocellular carcinoma in our center
between Jan 2005 and Dec 2009 were potentially eligible for enrollment
Exclusion Criteria:
- the recipient pass away within 3 month following up liver transplantation
- Inability to provide written informed consent prior to study entry
- acute rejection are treated only with steroids
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Outcome Measure:
patient and graft survival
Outcome Description:
patient and graft survival include surviral rate and recurrence-free survival rate
Outcome Time Frame:
Over 12-month after liver transplantation
Safety Issue:
No
Principal Investigator
Zhi-Hai Peng, MD
Investigator Role:
Study Chair
Investigator Affiliation:
Shanghai First People's Hospital
Authority:
China: Ethics Committee
Study ID:
20100603
NCT ID:
NCT01137084
Start Date:
January 2005
Completion Date:
December 2009
Related Keywords:
- Immunosuppression
- Hepatocellular Carcinoma
- Liver Transplantation
- Post-operative Complications
- Carcinoma
- Postoperative Complications
- Carcinoma, Hepatocellular
Name | Location |
|---|
